Journal article
Targeting fibrosis for the treatment of heart failure: A role for transforming growth factor-β
AJ Edgley, H Krum, DJ Kelly
Cardiovascular Therapeutics | WILEY | Published : 2012
Abstract
Chronic heart failure (CHF) is a growing health problem in developed nations. The pathological accumulation of extracellular matrix is a key contributor to CHF in both diabetic and nondiabetic states, resulting in progressive stiffening of the ventricular walls and loss of contractility. Proinflammatory disease processes, including inflammatory cytokine activation, contribute to accumulation of extracellular matrix in the heart. Transforming growth factor-β is a key profibrotic cytokine mediating fibrosis. Current therapeutic strategies do not directly target the profibrotic inflammatory processes occurring in the heart and hence there is a clear unmet clinical need to develop new therapeuti..
View full abstractGrants
Funding Acknowledgements
Henry Krum: HK has received grant and research support within the past 12 months from National Health and Medical Research Council, Medtronic, Scios, BUPA, Pfizer, and GlaxoSmithKline, and consultancy and speaker honoraria from Amgen, AstraZeneca, Medtronic, St Jude Medical, Roche, Novartis, Sanofi-Aventis, Pfizer, Mesoblast, and Gilead. HK is a member of the following advisory boards: Biotronik, Novartis, Sanofi - Aventis, Pfizer, Mesoblast, Apollo Life Sciences, and Gilead. Darren Kelly: DJK has received grant and research support within the past 12 months from National Health and Medical Research Council and Diabetes Australia Research Trust. Honoraria and grants from Novartis, Eli Lilly and Mesoblast. DJK is a director of Fibrotech Therapeutics.